Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange
08:30am, Thursday, 21'st Jan 2021
BERKELEY HEIGHTS, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preven
CorMedix Inc. Announces FDA Decision That Advisory Committee Meeting for New Drug Application for Defencath is Not Needed
08:30am, Wednesday, 18'th Nov 2020
BERKELEY HEIGHTS, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preven
CorMedix: Patent Coverage Is A Problem
06:47am, Friday, 13'th Nov 2020
Candidate could get approval. But IP not very strong.
CorMedix Inc. (CRMD) CEO Khoso Baluch on Q3 2020 Results - Earnings Call Transcript
02:31pm, Sunday, 08'th Nov 2020
CorMedix Inc. (CRMD) CEO Khoso Baluch on Q3 2020 Results - Earnings Call Transcript
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
06:55pm, Thursday, 05'th Nov 2020
CorMedix (CRMD) delivered earnings and revenue surprises of 15.38% and 116.28%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CorMedix's (CRMD) CEO Khoso Baluch On Q3 2020 Results - Quick Version Earnings Call Transcript
06:14pm, Thursday, 05'th Nov 2020
CorMedix's (CRMD) CEO Khoso Baluch On Q3 2020 Results - Quick Version Earnings Call Transcript
CorMedix Appoints Greg Duncan to its Board of Directors
08:30am, Monday, 02'nd Nov 2020
Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Seasoned industry veteran with decades of strategic and commercial leadership expe
CorMedix Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 5
08:30am, Thursday, 29'th Oct 2020
BERKELEY HEIGHTS, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preven
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) with the stream of 3.65% also noticed, India CorMedix Inc. (AMEX:CRMD) encountered a rapid change of 0.00% in the last hour of Friday’s trading session.
Astounding Stock: Chevron Corporation (NYSE:CVX), CorMedix Inc. (AMEX:CRMD) - Stocks Equity
01:16am, Monday, 05'th Oct 2020
Chevron Corporation (NYSE:CVX) with the stream of 1.09% also noticed, India CorMedix Inc. (AMEX:CRMD) encountered a rapid change of -2.66% in the last hour of Friday’s trading session. Chevron Corpo
Stock Runner: Transocean Ltd. (NYSE:RIG), CorMedix Inc. (AMEX:CRMD) - Stocks Equity
12:27am, Wednesday, 30'th Sep 2020
Transocean Ltd. (NYSE:RIG) with the stream of -3.75% also noticed, India CorMedix Inc. (AMEX:CRMD) encountered a rapid change of 9.67% in the last hour of Tuesday’s trading session. Transocean Ltd.
$50,000.00 in Sales Expected for CorMedix Inc. (NYSE:CRMD) This Quarter
05:48am, Friday, 18'th Sep 2020
Wall Street brokerages expect CorMedix Inc. (NYSE:CRMD) to report $50,000.00 in sales for the current quarter, according to Zacks. Two analysts have made estimates for CorMedix’s earnings, with esti
Foreshadowing Stock: CorMedix Inc. (AMEX:CRMD), Hewlett Packard Enterprise Company (NYSE:HPE) - Stocks Equity
03:20am, Wednesday, 16'th Sep 2020
CorMedix Inc. (AMEX:CRMD) with the stream of -2.14% also noticed, India Hewlett Packard Enterprise Company (NYSE:HPE) encountered a rapid change of -0.96% in the last hour of Tuesday’s trading sessi
Golden Stock: Guardion Health Sciences, Inc. (NASDAQ:GHSI), CorMedix Inc. (AMEX:CRMD) - Stocks Equity
03:48am, Friday, 11'th Sep 2020
Guardion Health Sciences, Inc. (NASDAQ:GHSI) with the stream of 0.85% also noticed, India CorMedix Inc. (AMEX:CRMD) encountered a rapid change of -0.66% in the last hour of Thursday’s trading sessio
NGM Bio Aldafermin Data, And Other News: The Good, Bad And Ugly Of Biopharma
06:52am, Sunday, 06'th Sep 2020
NGM Bio reports positive Phase 2 data for Aldafermin. CorMedix Inc.
